Aurinia Pharmaceuticals (AUPH) vs MBX Biosciences (MBX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
MBX Biosciences (MBX) has outperformed Aurinia Pharmaceuticals (AUPH) over the past year, gaining 235.8% versus a gain of 40.7%. MBX Biosciences is the larger company by market cap ($2.56 billion vs $2.16 billion), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AUPH | MBX |
|---|---|---|
| Share price | $16.22 | $53.25 |
| Market cap | $2.16B | $2.56B |
| 1-day change | +1.31% | -2.37% |
| YTD return | +1.69% | +68.83% |
| 1-year return | +40.68% | +235.75% |
| 5-year return | -21.15% | — |
| P/E ratio (TTM) | 7.11 | — |
| Forward P/E | 15.21 | — |
| EPS (TTM) | $2.28 | $-2.37 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | — | $-87.00M |
| 52-week high | $19.25 | $72.64 |
| 52-week low | $10.90 | $12.94 |
| Distance from 52-week high | -15.74% | -26.69% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +10.11% | +77.09% |
| Average volume | 988.90K | 539.34K |
| Shares outstanding | 133.05M | 48.16M |
| Employees | 128 | 63 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MBX has outperformed AUPH by 195.1 percentage points over the past year.
About Aurinia Pharmaceuticals
AUPH stock →Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis.
Health Care · Biotechnology: Pharmaceutical Preparations · 128 employees
About MBX Biosciences
MBX stock →MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism.
Health Care · Biotechnology: Pharmaceutical Preparations · 63 employees
AUPH vs MBX FAQ
Which is bigger, Aurinia Pharmaceuticals or MBX Biosciences?
MBX Biosciences (MBX) is larger, with a market capitalization of $2.56B compared with $2.16B for Aurinia Pharmaceuticals (AUPH).
Which stock has performed better over the past year, AUPH or MBX?
MBX returned +235.75% over the past 12 months, compared with +40.68% for AUPH (price return, excluding dividends). Past performance does not predict future results.
Are Aurinia Pharmaceuticals and MBX Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.